1.9466  -0.013 (-0.68%)		09-21 00:00
Open: 1.96 High: 1.99 Volume: 56,809		Pre. Close: 1.96 Low: 1.9286 Market Cap: 14(M)

Short term
Mid term
Targets	6-month :	1.81	1-year :	1.9
Resists	First :	1.55	Second :	1.62
Pivot price	1.5
Supports	First :	1.42	Second :	1.18
MAs	MA(5) :	1.47	MA(20) :	1.5
	MA(100) :	1.93	MA(250) :	2.25
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	24.8	D(3) :	26.3
RSI	RSI(14): 39.6
52-week	High :	7.67	Low :	0.34

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CLSN ] has closed above bottom band by 13.1%. Bollinger Bands are 68.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.5 - 1.51	1.51 - 1.52
Low:	1.41 - 1.42	1.42 - 1.43
Close:	1.44 - 1.46	1.46 - 1.47

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Thu, 14 Mar 2024
Imunon president and CEO steps down - NJBIZ

Tue, 20 Sep 2022
Celsion rebrands to Imunon to reflect immunotherapy plans - Fierce Biotech

Mon, 19 Sep 2022
Celsion Corporation Announces Company Name Change to Imunon, Inc. - GlobeNewswire

Mon, 28 Feb 2022
Celsion Corporation Announces Stock Consolidation - GlobeNewswire

Wed, 23 Jun 2021
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ... - GlobeNewswire

Thu, 23 Nov 2017
Celsion Turns Up The Heat On Cancer (NASDAQ:IMNN) - Seeking Alpha

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	-0.39
EPS Est This Year	-3.5
EPS Est Next Year	-1.17
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	-22.05
EBITDA (p.s.)	-4.41921e+006
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.07
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	2017-05-29
Ex-Dividend Date	Invalid DateTime.